by @shorten2trial.bsky.social
Stay updated on the latest in the treatment, diagnosis and cutting-edge research of Pseudomonas aeruginosa. Join us with the tag #PsWatch #IDSky #MicroSky
MD Hasib Sarder NET KOSPET ORB 2 Rugged Smartwatch Review 1.43" AMOLED, Dual-Band GPS, LED Flashlight & IP69 Waterproof #SuqMall #KOSPETORB2 #KOSPET #KOSPETSmartwatch #SmartwatchBangladesh #RuggedSmartwatch #MilitarySmartwatch #AMOLEDSmartwatch #DualBandGPS #GPSWatch #OutdoorSmartwatch #WaterproofSmartwatch
The Journal of Infectious Diseases Translational and phase I evaluation of AZD0292, a novel, half-life extended anti-Pseudomonal Psl-PcrV bispecific monoclonal antibody ✅ Just Accepted 🔗 https://bit.ly/4ekWUm3
SHORTEN-2 trial Our @shorten2trial.bsky.social aims to confirm that 7-day treatments are superior to 14-day courses for uncomplicated P. aeruginosa BSI. Check out our full protocol 👉🏻 journals.plos.org/plosone/arti... #AMSsky #IDSky
SHORTEN-2 trial What's the best duration for treating uncomplicated P. aeruginosa-BSI? This metaanalysis of observational studies (n=1746) found no differences in recurrence+mortality for short (<10d) compared to prolonged treatments. 📖 www.journalofhospitalinfection.com/article/S019... #PsWatch #AMSsky #IDsky
SHORTEN-2 trial Despite our growing antibiotic arsenal, non-fermenting GNB frequently keep leaving us without therapeutic options. This article explores the present and the future of therapies against DTR NF-GNB: journals.lww.com/co-infectiou... #PsWatch #AMSsky #IDsky
SHORTEN-2 trial Only 58 patients to go! Recruitment is moving along as planned, and fingers crossed, we’ll be done before summer. Huge shoutout to the @shorten2trial.bsky.social team for keeping up the great work! #AMSsky #IDSky #ShorterIsBetter
SHORTEN-2 trial Today we celebrated our 3rd Annual Researchers’ Meeting at the XXVIII Congress of @seimc.bsky.social! Only 2️⃣4️⃣ patients left to complete the trial! An amazing team doing an amazing work! 🤩🔝 #IDSky #AMSsky #TeamPride
SHORTEN-2 trial This metaanalysis of observational studies in SOT suggests that non-complicated graft infections could be treated 7d, and yet transplant patients have been excluded from most RCT on duration. Time for a #ShorterIsBetter RCT in #TxID! kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky
SHORTEN-2 trial Recruitment for SHORTEN-2 is officially complete! Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026! Hats off to this awesome research team! 🥳 #AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
SHORTEN-2 trial This post hoc analysis of the subgroup of patients with P. aeruginosa BSI recruited for the BALANCE RCT showed no differences in 90d mortality between patients treated for 7 vs 14d. However, sample size and wide CIs preclude definite conclusions. academic.oup.com/cid/advance-... #IDsky #AMSsky
SHORTEN-2 trial Combined antipseudomonal therapy does not improve outcomes and may increase toxicity. Its main role is ensuring appropriate empirical therapy in severe infections, with no proven benefit once susceptibility is known. 📖 A systematic review: www.tandfonline.com/doi/full/10.... #AMSsky #IDsky #PsWatch
SHORTEN-2 trial We’re happy to share that results of the @shorten2trial.bsky.social will be presented at the #XXIXCongresoSEIMC! 📆 Friday, May 29 - 14:25h 📍Room 0D 📻 Stay tuned! #AMSsky #IDSky @absteward.bsky.social @idstewardship.bsky.social @bradspellberg.bsky.social @drtoddlee.bsky.social @esgap.bsky.social
SHORTEN-2 trial SHORTEN2 results have been presented at #CongresoSEIMC2026! 7-day treatments were shown superior to 14-day in reducing antibiotic exposure and adverse events while maintaining efficacy. Fantastic work by >100 researchers across 37 Spanish hospitals! #TeamPride #IDsky #AMSsky @seimc.bsky.social
SHORTEN-2 trial The OPTIMISE trial aimed to test 7 vs 14 days for treating MDR infections in ICU patients. Although underpowered due to early stop, no signal of inefficacy was observed for short treatments Pseudomonas were underrepresented in this trial 🙁 link.springer.com/article/10.1... #AMSsky #IDsky #PsWatch